| |
 |
Editorial [Hot Topic:Are the Pleiotropic Effects of Drugs Used for the Prevention of Cardiovascular Disease Clinically Relevant?(Executive Editors: M. Elisaf and E.N. Liberopoulos)]
|
| |
|
pp.463-466 (4) Authors: Moses Elisaf, Evangelos N. Liberopoulos
|
| |
|
|
| |
|
Statins and Cardiovascular Diseases: From Cholesterol Lowering to Pleiotropy
|
| |
|
pp.467-478 (12) Authors: Qian Zhou, James K. Liao
|
| |
|
|
| |
|
Pleiotropic Effects of Statins - Clinical Evidence
|
| |
|
pp.479-489 (11) Authors: Vasilios G. Athyros, Anna I. Kakafika, Konstantinos Tziomalos, Asterios Karagiannis, Dimitri P. Mikhailidis
|
| |
|
|
| |
|
Lipid-Lowering Drugs Acting at the Level of the Gastrointestinal Tract
|
| |
|
pp.490-516 (27) Authors: T. D. Filippatos, D. P. Mikhailidis
|
| |
|
|
| |
|
Pleiotropic Effects of Fenofibrate
|
| |
|
pp.517-528 (12) Authors: V. Tsimihodimos, E. Liberopoulos, M. Elisaf
|
| |
|
|
| |
|
Effects of Thiazolidinediones Beyond Glycaemic Control
|
| |
|
pp.529-536 (8) Authors: Rigas G. Kalaitzidis, Pantelis A. Sarafidis, George L. Bakris
|
| |
|
|
| |
|
Fibrates and Microvascular Complications in Diabetes - Insight from the FIELD Study
|
| |
|
pp.537-552 (16) Authors: J. C. Ansquer, C. Foucher, P. Aubonnet, K. Le Malicot
|
| |
|
|
| |
|
Pleiotropic Effects of Rimonabant: Clinical Implications
|
| |
|
pp.553-570 (18) Author: Jean-Pierre Despres
|
| |
|
|
| |
|
Pleiotropic Effects of Drugs Inhibiting the Renin-Angiotensin-Aldosterone System
|
| |
|
pp.571-584 (14) Authors: P. Jankowski, M. E. Safar, A. Benetos
|
| |
|
|
